• Home
  • Commercial & Medical
  • Lilly’s orforglipron is the first oral obesity therapy to show its worth in the maintenance setting

Lilly’s orforglipron is the first oral obesity therapy to show its worth in the maintenance setting

Eli Lilly’s experimental obesity pill allowed patients who had lost weight on injected GLP-1-based drugs to keep most of the weight off for another year, according to data from a Phase 3 trial released Thursday …

Subscribe for Updates

Copyright 2025 dijee Intelligence Ltd.   dijee Intelligence Ltd. is a private limited company registered in England and Wales at Media House, Sopers Road, Cuffley, Hertfordshire, EN6 4RY, UK registeration number 16808844